Human CD45 peptide (ab17550)
- Product nameHuman CD45 peptideSee all CD45 proteins and peptides ...
Our Abpromise guarantee covers the use of ab17550 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
- Concentration information loading...
Preparation and Storage
- Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
- CD 45
- CD45 antigen
- L CA
- Leukocyte common antigen
- Protein tyrosine phosphatase receptor type C
- Protein tyrosine phosphatase receptor type c polypeptide
- protein tyrosine phosphatase, receptor type, C
- Receptor-type tyrosine-protein phosphatase C
- SCID due to PTPRC deficiency
- T200 glycoprotein
- T200 leukocyte common antigen
- FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
- Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
- Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains.
- DomainThe first PTPase domain interacts with SKAP1.
modificationsHeavily N- and O-glycosylated.
- Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
Human CD45 peptide images
Expected molecular weight: 147 kDa. WB exposure time: 1min 30sec
Lanes 1 to 10: 20
g of cell lysate per lane µ
Lanes 6 to 10: ab17550 CD45 blocking peptide used at 1
Lane 1: HeLa Nuclear Extract (ab10559)
Lane 2: HeLa Whole Cell Lysate (ab10559)
Lane 3: A431 Whole Cell Lysate (ab10559)
Lane 4: Jurkat Whole Cell Lysate (ab10559)
Lane 5: HEK293 Whole Cell Lysate (ab10559)
Lane 6: HeLa Nuclear Extract (ab10559+ ab17550)
Lane 7: HeLa Whole Cell Lysate (ab10559+ ab17550)
Lane 8: A431 Whole Cell Lysate (ab10559+ ab17550)
Lane 9: Jurkat Whole Cell Lysate (ab10559+ ab17550)
Lane 10: HEK293 Whole Cell Lysate (ab10559+ ab17550)
Binding of ab10559 to Jurkat cell lysate was blocked using ab17550.
References for Human CD45 peptide (ab17550)
ab17550 has not yet been referenced specifically in any publications.